Teligent Pharma, Inc. is recalling 30,696 units of Erythromycin Topical Solution USP, 2% (60 mL) and Erythromycin Topical Gel, 2% (30 g and 60 g). These prescription medications were found to fail required tests for impurities and degradation specifications during stability testing. Using a product that has degraded may mean the medication is less effective at treating skin conditions like acne or contains higher-than-allowed levels of chemical breakdown products. Consumers should contact their healthcare provider or pharmacist for guidance on alternative treatments and return the affected products to their place of purchase for a refund.
The medications failed to meet chemical stability standards, which can lead to the formation of impurities or the breakdown of the active ingredients. While the risk level is considered low, degraded medication may not work properly to treat the intended condition.
Consult health provider and return product.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.